Major clinical response in a patient with leukemia cutis treated with the bromodomain inhibitor PLX51107 and azacitidine
Kunhwa Kim(The University of Texas MD Anderson Cancer Center), Naveen Pemmaraju(The University of Texas MD Anderson Cancer Center), Marina Konopleva(Albert Einstein College of Medicine), Jonathan L. Curry(The University of Texas MD Anderson Cancer Center), Sherry Pierce(The University of Texas MD Anderson Cancer Center), Naval Daver(The University of Texas MD Anderson Cancer Center), Sanam Loghavi(The University of Texas MD Anderson Cancer Center), Alexandre Bazinet(The University of Texas MD Anderson Cancer Center), Nathaniel R. Wilson(The University of Texas Health Science Center at Houston), Gautam Borthakur(The University of Texas MD Anderson Cancer Center), Kapil N. Bhalla(The University of Texas MD Anderson Cancer Center), Meghan Heberton(Southwestern Medical Center), Darla Miller(The University of Texas MD Anderson Cancer Center), Joseph D. Khoury(University of Nebraska Medical Center), Tapan M. Kadia(The University of Texas MD Anderson Cancer Center)
Cited by 1
Related Papers
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms
|Leukemia|2022|3.8k
Inhibition of Histone Deacetylase 6 Acetylates and Disrupts the Chaperone Function of Heat Shock Protein 90
|Journal of Biological Chemistry|2005|749
2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party
|Blood|2021|714
PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia
|Nature Genetics|2019|616